Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
复制标题
DOI：
10.1186/s12902-018-0303-x
复制
发表时间：
2018-11-03
影响因子：
2.7
通讯作者：
Gulias-Herrero A
中科院分区：
文献类型：
--
作者：
Gómez-Sámano MÁ;Baquerizo-Burgos JE;Coronel MFC;Wong-Campoverde BD;Villanueva-Martinez F;Molina-Botello D;Avila-Rojo JA;Palacios-Báez L;Cuevas-Ramos D;Gomez-Perez FJ;Zentella-Dehesa A;Aguayo-González Á;Gulias-Herrero A
2型糖尿病已成为全球最重要的公共卫生问题之一。由于其高患病率和发病率，迫切需要找到减缓疾病进展并促进疾病消退的新疗法。甲磺酸伊马替尼是一种酪氨酸激酶抑制剂，与Abelson酪氨酸激酶和相关蛋白结合。它增强β细胞对毒素和促炎细胞因子的反应。本研究的目的是评价伊马替尼对空腹血糖正常受试者、空腹血糖受损受试者和2型糖尿病受试者空腹血糖的影响。我们从萨尔瓦多祖比兰国家科学与营养研究所的数据库中确定了284名被诊断为慢性髓性白血病或胃肠道间质瘤的受试者。106/284例受试者接受伊马替尼治疗。我们比较了伊马替尼治疗1个月和6个月后对空腹血糖的影响。我们使用重复样本的ANOVA检验来确定伊马替尼治疗前和随访时空腹血糖的统计学意义。使用社会科学统计软件包v22进行统计分析。我们共纳入106例受试者：76例空腹血糖浓度< 100 mg/dL（FG正常），19例空腹血糖浓度≥100 mg/dL（空腹血糖受损），11例≥126 mg/dL（2型糖尿病）。我们发现空腹血糖正常组的空腹血糖浓度显著升高（p = 0.048），2型糖尿病组的空腹血糖浓度显著降低（p = 0.042）。在空腹血糖受损组中，我们还发现空腹血糖有下降的趋势（p = 0.076）。我们确定了11例2型糖尿病受试者，其中7例（64%）在6个月后空腹血糖浓度降低。观察到糖化血红蛋白显著降低（p = 0.04）。慢性髓性白血病或胃肠道间质瘤伴2型糖尿病受试者在使用伊马替尼后1个月和6个月空腹血糖和糖化血红蛋白显著降低。本文的在线版本（10.1186/s12902-018-0303-x）包含补充材料，可供授权用户使用。
Type 2 diabetes mellitus has become one of the most important public health concerns worldwide. Due to its high prevalence and morbidity, there is an avid necessity to find new therapies that slow the progression and promote the regression of the disease. Imatinib mesylate is a tyrosine kinase inhibitor that binds to the Abelson tyrosine kinase and related proteins. It enhances β-cell survival in response to toxins and pro-inflammatory cytokine. The aim of this study is to evaluate the effect of imatinib on fasting plasma glucose in subjects with normal fasting glucose, subjects with impaired fasting glucose and in subjects with type 2 diabetes mellitus. We identified 284 subjects diagnosed with chronic myeloid leukemia or gastrointestinal stromal tumors from the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran database. 106/284 subjects were treated with imatinib. We compared the effect of imatinib on fasting plasma glucose after 1 and 6 months of treatment. We used ANOVA test of repeated samples to determine statistical significance in fasting plasma glucose before imatinib treatment and the follow-up. Statistical analysis was performed with Statistical Package for the Social Sciences v22. We included a total of 106 subjects: 76 with fasting plasma glucose concentrations < 100 mg/dL (normal FG), 19 subjects with fasting plasma glucose concentrations ≥100 mg/dL (impaired fasting glucose), and 11 subjects with ≥126 mg/dL (type 2 diabetes mellitus). We found a significant increase in fasting plasma glucose concentration in the normal fasting glucose group (p = 0.048), and a significant decrease in fasting plasma glucose concentration in the type 2 diabetes mellitus group (p = 0.042). In the impaired fasting glucose group, we also found a tendency towards a decrease in fasting plasma glucose (p = 0.076). We identified 11 subjects with type 2 diabetes mellitus, of whom, 7 (64%) had a reduction in their fasting plasma glucose concentrations after 6 months. A significant glycosylated hemoglobin reduction (p = 0.04) was observed. Subjects with chronic myeloid leukemia or gastrointestinal stromal tumor with type 2 diabetes mellitus had a significant reduction in fasting plasma glucose and glycosylated hemoglobin at 1 and 6 months while using imatinib. The online version of this article (10.1186/s12902-018-0303-x) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
8
作者：
Tuveson, DA;Willis, NA;Demetri, GD
通讯作者：
Demetri, GD
影响因子：
4.8
作者：
Hagerkvist, Robert;Sandler, Stellan;Welsh, Nils
通讯作者：
Welsh, Nils
影响因子：
7.7
作者：
Prada PO;Ropelle ER;Mourão RH;de Souza CT;Pauli JR;Cintra DE;Schenka A;Rocco SA;Rittner R;Franchini KG;Vassallo J;Velloso LA;Carvalheira JB;Saad MJ
通讯作者：
Saad MJ
影响因子：
5.8
作者：
Fitter, Stephen;Vandyke, Kate;Zannettino, Andrew C. W.
通讯作者：
Zannettino, Andrew C. W.
影响因子：
3.7
作者：
Xia CQ;Zhang P;Li S;Yuan L;Xia T;Xie C;Clare-Salzler MJ
通讯作者：
Clare-Salzler MJ